Claritas Rx introduces Consent Clearinghouse(TM) to modernize Patient Consent Management across biopharma. New Solution Gives Oncology and Rare Disease Teams a Centralized, Compliant View of Patient Consent Across the Full Therapy Journey New White Paper from Claritas Rx Entitled "Why Consent Management is Biopharma's Blind Spot" Now Available SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Claritas Rx, the patient journey experts, today announced Consent Clearinghouse(TM), a dedicated solution for standardizing and centralizing patient consent across oncology, rare disease, and specialty biopharma. "Real-time visibility into consent status isn't just about reducing compliance risk today; it's about building the trust infrastructure that will define how brands responsibly scale patient engagement tomorrow," said Mike Fitzgibbons, CEO of Claritas Rx. Share As biopharma companies navigate an increasingly complex regulatory environment, including HIPAA, GDPR, CCPA, a growing patchwork of state privacy laws, and the emerging rules governing the use of AI, managing patient consent across multiple data sources, specialty pharmacies, hubs, and channel partners has become a critical operational and compliance challenge. Consent Clearinghouse addresses this directly by providing a single, auditable source of truth for consent data across all touchpoints. Consent Clearinghouse integrates consent data from across a brand's ecosystem, including hubs, specialty pharmacies, field reimbursement managers, copay programs, and IOD/IDN channels, into a unified dashboard. Commercial and market access teams gain real-time visibility into consent status, enabling them to act on data with confidence while reducing compliance risk. "Commercial and market access teams can no longer afford to operate on fragmented consent data - the pace of AI-driven engagement has raised the stakes too high. Real-time visibility into consent status isn't just about reducing compliance risk today; it's about building the trust infrastructure that will define how brands responsibly scale patient engagement tomorrow," said Michael Fitzgibbons, CEO of Claritas Rx. "We built Consent Clearinghouse to give biopharma teams the visibility and control they need to operate compliantly, move faster, and ultimately serve more patients. This is particularly critical for patients in oncology and rare disease who can't afford delays caused by missing or mismanaged consent." Key Consent Clearinghouse capabilities include: * Unified consent tracking across all patient touchpoints and data sources * Real-time dashboard providing consent status visibility at the patient, brand, and channel level * Audit-ready reporting to support HIPAA, GDPR, CCPA, and state privacy compliance * Seamless integration with existing CRM, hub, and specialty pharmacy platforms * Role-based access controls to protect sensitive patient data across teams and partners With experience supporting numerous brands across oncology, rare, and specialty therapeutic areas, Claritas Rx designed Consent Clearinghouse specifically for the complex, high-stakes environment of specialty and rare disease therapies, where patient access barriers and compliance requirements are greatest. Consent and Compliance Thought Leadership Consent management is no longer just a compliance issue; it is a patient access issue. Claritas Rx's new white paper, "Why Consent Management is Biopharma's Blind Spot," breaks down where consent gaps form, what they cost, and how leading biopharma teams are building a more unified, audit-ready approach across the full therapy journey. A companion webinar, "The Hidden Risk in Your Access Strategy: Rethinking Patient Consent Management," will take place on August 19 at 10 am PT (1 pm ET). Media may request a copy of the white paper or registration to the webinar by contacting Emily Brennan. About Claritas Rx Based in South San Francisco, CA, Claritas Rx helps rare disease and specialty brands remove the barriers that keep patients from accessing and staying on the treatments they need. By uniting the most complete view of the patient journey with purpose-built technologies, Business Wire, Inc. predict and resolve access challenges before they disrupt care. Its intelligent solutions combine advanced analytics, real-world data, AI, and in-line CRM capabilities to increase start and refill rates, reduce abandonment, and improve brand performance. For more information, visit www.ClaritasRx.com. More News From Claritas Rx SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, announced new leadership appointments designed to continue growth and scale. The company has welcomed Keith Pensabene as Chief Revenue Officer (CRO) and has promoted Meghna Misra to Vice President, Product and Shelly Howard to Vice President, Customer Operations. Mr. Pensabene brings more than 25 years of executive sales and revenue leadership experience across the life sciences and enterprise software secto... SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, today announced that Bhupesh Bajaj, Chief Technology Officer, has been named to the prestigious PM360 ELITE 100 list in the Data Miners category. The annual recognition highlights the most exceptional, innovative, and transformative leaders shaping the healthcare and life sciences industries today. Mr. Bajaj was recognized for his groundbreaking work redefining how data is harnessed to drive meaningful outco... SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, today announced the availability of its Patient Services Omnichannel CRM. The new solution enables clients to engage rapidly and consistently across the full patient-care ecosystem - from specialty and independent pharmacies to hubs, field teams, case managers, and other key stakeholders - accelerating patient support and streamlining communication for a faster, better experience at every stage of care. By unify... Claritas Rx. Release Versions

Claritas Rx, a patient journey analytics company based in South San Francisco, has appointed Keith Pensabene as Chief Revenue Officer and promoted two executives to vice president roles. Meghna Misra has been elevated to Vice President, Product, whilst Shelly Howard becomes Vice President, Customer Operations. Pensabene brings over 25 years of executive sales and revenue leadership experience from companies including IQVIA, Blue Mountain and Accenture. Misra previously held senior product roles at Microsoft, Intuit and Pure Storage, and has been instrumental in developing Claritas Rx's Ascend platform. Howard has more than 25 years in biotech and pharmaceutical operations, including 15 years at Genentech. The appointments aim to support the company's growth and scaling efforts in the rare disease and specialty pharmaceutical sectors.

Claritas Rx has launched its Patient Services Omnichannel CRM, designed to accelerate patient access to specialty therapies by connecting pharmacies, hubs, field teams and case managers on a single platform. The solution uses AI-driven orchestration to provide predictive risk detection, next-best-action insights and optimised communication recommendations. Built specifically for specialty pharmaceutical manufacturers, the CRM addresses fragmented workflows and inefficient communication in patient services. When combined with Claritas Rx's Patient Watchtower system, the platform creates a unified operating layer that links journey analytics with coordinated front-line action. The company reports clients achieved a 98% response rate within 24 hours from specialty pharmacy and hub partners using the combined solutions. The platform aims to improve adherence and patient outcomes whilst minimising implementation and maintenance costs.